Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately

Core Viewpoint - A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging that the company made materially false and misleading statements regarding its drug relacorilant during the class period from October 31, 2024, to December 30, 2025 [1][2]. Group 1: Allegations Against Corcept - Defendants allegedly overstated the strength of clinical trials supporting relacorilant, misrepresenting them as "powerful support" for the New Drug Application (NDA) to the FDA [2]. - The complaint claims that defendants falsely conveyed confidence in relacorilant's regulatory prospects, stating they had communicated with the FDA and anticipated no impediments to approval, despite the FDA raising concerns about the adequacy of clinical evidence [2]. - As a result of these actions, defendants failed to disclose the material risk that Corcept's relacorilant NDA might not be approved, making their statements about the company's business and prospects misleading [2]. Group 2: Investor Information - Investors who suffered losses related to Corcept's securities have until April 21, 2026, to seek appointment as lead plaintiff in the class action lawsuit [3].